These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36483225)

  • 1. Erythrodermic psoriasis improved by Tildrakizumab.
    Trevisan G; Germi L; Naldi L
    Dermatol Reports; 2022 Nov; 14(4):9448. PubMed ID: 36483225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab.
    Megna M; Ruggiero A; Salsano A; Lauletta G; Portarapillo A; Torta G; Martora F; Potestio L
    Clin Cosmet Investig Dermatol; 2023; 16():3503-3507. PubMed ID: 38077922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
    Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tildrakizumab for the treatment of psoriasis.
    Bangert C; Kopp T
    Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tildrakizumab for Moderate-to-Severe Plaque Psoriasis.
    Mui UN; Patel RR; Vangipuram R; Tyring SK
    Skin Therapy Lett; 2019 Nov; 24(6):1-4. PubMed ID: 31801012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
    Paton DM
    Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of erythrodermic psoriasis successfully treated with guselkumab.
    Megna M; Ruggiero A; Camela E; Fabbrocini G; Marasca C
    Dermatol Ther; 2020 Mar; 33(2):e13238. PubMed ID: 31997488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.
    Megna M; Fabbrocini G; Ferrillo M; Cinelli E
    Dermatol Ther; 2020 Nov; 33(6):e14351. PubMed ID: 32981222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge.
    Ruggiero A; Camela E; Potestio L; Fabbrocini G; Megna M
    Expert Opin Drug Saf; 2022 Dec; 21(12):1445-1451. PubMed ID: 36527300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tildrakizumab for treating psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of erythrodermic psoriasis successfully treated with ixekizumab.
    Megna M; Gallo L; Balato N; Balato A
    Dermatol Ther; 2019 Mar; 32(2):e12825. PubMed ID: 30650216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
    Frampton JE
    Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythrodermic Psoriasis Successfully Treated with Anti IL-17: A Case Series.
    Bernardini N; Skroza N; Proietti I; Mambrin A; Marchesiello A; Tolino E; Balduzzi V; Potenza C
    Acta Dermatovenerol Croat; 2021 Nov; 29(4):191-195. PubMed ID: 36896689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tildrakizumab: A Review of Phase II and III Clinical Trials.
    Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
    Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date.
    Beck KM; Sanchez IM; Yang EJ; Liao W
    Psoriasis (Auckl); 2018; 8():49-58. PubMed ID: 30214892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis.
    Näslund-Koch C; Zachariae C; Skov L
    Ther Clin Risk Manag; 2020; 16():903-916. PubMed ID: 33061395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics for the Management of Erythrodermic Psoriasis: An Updated Review.
    Potestio L; Camela E; Cacciapuoti S; Fornaro L; Ruggiero A; Martora F; Battista T; Megna M
    Clin Cosmet Investig Dermatol; 2023; 16():2045-2059. PubMed ID: 37560255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.
    Shao S; Wang G; Maverakis E; Gudjonsson JE
    Drugs; 2020 Apr; 80(6):525-534. PubMed ID: 32180204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
    Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
    Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.